Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg
NCT01017679
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
96
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
Gefitinib 500mg/Gefitinib 250mg
Sponsor
Sun Yat-sen University
Collaborators
[object Object]